SCHEDULE: EcoR1 Capital Discloses 4.8% Stake in Kura Oncology
Beneficial Ownership Report
EcoR1 Capital, LLC and affiliated entities reported a passive beneficial ownership of 4.8% in Kura Oncology, Inc. common stock as of June 30, 2025.
Summary
- EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Kura Oncology, Inc.
- As of June 30, 2025, EcoR1 Capital, LLC and Oleg Nodelman each beneficially owned 4,200,000 shares of Kura Oncology, Inc. Common Stock, representing 4.8% of the class.
- EcoR1 Capital Fund Qualified, L.P. beneficially owned 3,937,232 shares, representing 4.5% of the class.
- The percentages are calculated based on 86,797,185 shares of Common Stock outstanding on August 1, 2025, as reported in Kura Oncology's Form 10-Q for the quarter ended June 30, 2025.
- All reporting persons hold shared voting and dispositive power over their reported shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a neutral sentiment as it provides factual information without expressing positive or negative outlooks on the company's performance.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Kura Oncology, Inc.'s future performance or strategic direction.
Industry Context
This filing reflects a passive investment by a specialized healthcare investment firm, EcoR1 Capital, in a biotechnology company. Such disclosures are routine for institutional investors holding significant, but non-controlling, stakes in public companies, indicating continued interest in the sector and specific company.
Comparison to Industry Standards
- NA
Related Party Transactions
- EcoR1 Capital, LLC is the general partner and investment adviser of investment funds, including EcoR1 Capital Fund Qualified, L.P. Oleg Nodelman is the control person of EcoR1 Capital, LLC, establishing a relationship between the reporting entities for joint filing purposes.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, confirming a passive stake by EcoR1 Capital, LLC and its affiliates.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (end of quarter for ownership reporting). |
| 08/01/2025 | Date on which 86,797,185 shares of Common Stock were reported outstanding by Kura Oncology, Inc. |
| 08/14/2025 | Date of signing for the Schedule 13G filing. |
Keywords
Kura Oncology, EcoR1 Capital, Oleg Nodelman, Beneficial Ownership, Common Stock, Biotechnology, Investment, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.